Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1054/bjps.2002.3896 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Use of Diced Cartilage for Management of Internal Mammary Vessel Exposure Sites in Autologous Breast Reconstruction.
Plast Reconstr Surg Glob Open
January 2025
From the Department of Plastic, Reconstructive and Aesthetic Surgery, ISAR Klinikum, Munich, Germany.
Background: Exposure of internal mammary vessels in autologous breast reconstruction often requires removal of a rib cartilage segment, which can lead to breast contour deformity. This study evaluated the use of diced cartilage (DC) to counteract substance loss in the microvascular anastomosis area.
Methods: This retrospective, single-center cohort study included all breast reconstructions in which DC was used from October 2021 to June 2023.
Hot Quadrate Sign Under Focus of F18-FDG PET-CT: An Incidental Finding.
J Pak Med Assoc
January 2025
Department of Nuclear Medicine, Shaukat Khanum Memorial Cancer Hospital and Research Center, Lahore.
"Hot quadrate lobe sign" refers to visualization of caudate lobe of liver due to excess accumulation of radiotracer secondary to superior vena cava obstruction. Collateral channels are formed between thoracic and mediastinal vessels; internal mammary through the paraumbilical vessels which drain blood to the left portal vein and into the caudate lobe of liver. It was first described on Tc99-m sulfur colloid scan.
View Article and Find Full Text PDFAdvancing treatment choices: CDK4/6 inhibitor switching in HR+/HER2- metastatic breast cancer.
Breast
January 2025
Medical Oncology Division and Breast Unit, Senatore Antonio Perrino Hospital, ASL Brindisi, Brindisi, Italy.
Purpose: CDK4/6 inhibitors (CDK4/6i) use has revolutionized the treatment of hormone receptor-positive/human epidermal growth factor receptor 2 negative (HR+/HER2-) metastatic breast cancer. The choice of a specific CDK4/6i may be influenced by adverse events (AEs). Recently, the Italian Medicines Agency (AIFA) approved the possibility of switching between CDK4/6i for unacceptable toxicity.
View Article and Find Full Text PDFEfficacy and safety of KN026 and docetaxel for HER2-positive breast cancer: a phase II clinical trial.
Cancer Commun (Lond)
January 2025
Department of Medical Oncology, Cancer Hospital, Harbin Medical University, Harbin, Heilongjiang, P. R. China.
Background: The standard first-line treatment for human epidermal growth factor receptor 2 (HER2)-positive recurrent/metastatic breast cancer currently includes pertuzumab plus trastuzumab and docetaxel. This study aimed to evaluate the effectiveness of KN026, an anti-HER2 bispecific antibody, plus docetaxel in first-line treatment of HER2-positive recurrent/metastatic breast cancer.
Methods: This open-label, single-arm, phase II study enrolled patients with HER2-positive recurrent/metastatic breast cancer in 19 centers across China from December 30, 2019 to May 27, 2021.
A Phase II Trial of Onapristone and Fulvestrant for Patients With ER+ and HER2- Metastatic Breast Cancer.
Clin Breast Cancer
December 2024
Medical Oncology and Palliative Care, Department of Medicine, Breast Cancer Disease Oriented Team, University of Wisconsin Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, WI 53792-3252.
Background: The SMILE study is a multi-institutional phase II clinical trial to determine the efficacy and safety of an antiprogestin, onapristone, in combination with fulvestrant as second-line therapy for patients with ER+, PgR+/-, HER2- metastatic breast cancer. This study was terminated early and herein, we report patient characteristics, and outcomes.
Methods: Eligibility criteria included disease progression on ≥2 lines of prior therapy, ECOG performance status ≤ 2, measurable disease per RECIST 1.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!